BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...Sirnaomics Inc. (Gaithersburg, Md.) hired Allan Shaw as CFO. He is a board member of Vivus Inc....
BioCentury | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

...global commercial products at Orexigen Therapeutics Inc. (La Jolla, Calif.). Cardiovascular, metabolic and pulmonary company Vivus Inc....
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc....
...La Jolla, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of New South Wales, Sydney, Australia Vivus Inc....
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

...enlarge the GLP-1 market.” Lars Fruergaard Jørgensen, Novo Nordisk The next largest obesity product was Vivus Inc....
...the three obesity drugs launched over 2012-14, with placebo-adjusted reductions in body weight of 3.5-9.4%. Vivus...
...A/S (CSE:NOVOB; NYSE:NVO), Bagsvaerd, Denmark Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Oxford, Oxford, U.K. Vivus Inc....
BioCentury | Mar 3, 2017
Finance

Earnings on deck

...EPS est 4Q15 EPS Expected chg SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 3/6 Pre NA $0.30 NA Vivus Inc....
BioCentury | Jan 13, 2017
Company News

Selten, Vivus deal

...Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary...
...financial terms, and Selten referred questions to Vivus. Selten Pharma Inc. , San Carlos, Calif. Vivus Inc....
...Selten Pharma Inc. , San Carlos, Calif. Vivus Inc. (NASDAQ:VVUS), Campbell, Calif. Business: Cardiovascular Nora Weintraub Selten Pharma Inc. Vivus Inc....
BioCentury | Nov 4, 2016
Finance

Earnings on deck

...NASDAQ:JAZZ) 11/8 Post $2.61 $2.52 4% SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 11/9 Post NA $0.23 NA Vivus Inc....
BioCentury | Oct 10, 2016
Company News

Vivus, Mist Pharmaceuticals deal

...to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus...
...will be responsible for undisclosed royalties payable to Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan). Vivus...
...Japan, China and certain other Pacific Rim countries. Stendra is a fast-acting phosphodiesterase-5 (PDE-5) inhibitor. Vivus Inc....
BioCentury | Aug 1, 2016
Finance

Gilead's arithmetic problem

...Inc. (NYSE:EBS) 8/4 Post -$0.17 $0.36 NA PerkinElmer Inc. (NYSE:PKI) 8/4 Post $0.66 $0.60 10% Vivus Inc....
Items per page:
1 - 10 of 707
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...Sirnaomics Inc. (Gaithersburg, Md.) hired Allan Shaw as CFO. He is a board member of Vivus Inc....
BioCentury | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

...global commercial products at Orexigen Therapeutics Inc. (La Jolla, Calif.). Cardiovascular, metabolic and pulmonary company Vivus Inc....
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc....
...La Jolla, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of New South Wales, Sydney, Australia Vivus Inc....
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

...enlarge the GLP-1 market.” Lars Fruergaard Jørgensen, Novo Nordisk The next largest obesity product was Vivus Inc....
...the three obesity drugs launched over 2012-14, with placebo-adjusted reductions in body weight of 3.5-9.4%. Vivus...
...A/S (CSE:NOVOB; NYSE:NVO), Bagsvaerd, Denmark Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Oxford, Oxford, U.K. Vivus Inc....
BioCentury | Mar 3, 2017
Finance

Earnings on deck

...EPS est 4Q15 EPS Expected chg SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 3/6 Pre NA $0.30 NA Vivus Inc....
BioCentury | Jan 13, 2017
Company News

Selten, Vivus deal

...Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary...
...financial terms, and Selten referred questions to Vivus. Selten Pharma Inc. , San Carlos, Calif. Vivus Inc....
...Selten Pharma Inc. , San Carlos, Calif. Vivus Inc. (NASDAQ:VVUS), Campbell, Calif. Business: Cardiovascular Nora Weintraub Selten Pharma Inc. Vivus Inc....
BioCentury | Nov 4, 2016
Finance

Earnings on deck

...NASDAQ:JAZZ) 11/8 Post $2.61 $2.52 4% SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 11/9 Post NA $0.23 NA Vivus Inc....
BioCentury | Oct 10, 2016
Company News

Vivus, Mist Pharmaceuticals deal

...to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus...
...will be responsible for undisclosed royalties payable to Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan). Vivus...
...Japan, China and certain other Pacific Rim countries. Stendra is a fast-acting phosphodiesterase-5 (PDE-5) inhibitor. Vivus Inc....
BioCentury | Aug 1, 2016
Finance

Gilead's arithmetic problem

...Inc. (NYSE:EBS) 8/4 Post -$0.17 $0.36 NA PerkinElmer Inc. (NYSE:PKI) 8/4 Post $0.66 $0.60 10% Vivus Inc....
Items per page:
1 - 10 of 707